Ratain, Mark J.

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis

The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Domingo, P., Mur, I., Mateo, G. M., Gutierrez, M. D. M., Pomar, V., de Benito, N., Corbacho, N., Herrera, S., Millan, L., et al. (2021) · JAMA

COVID-19 Clinical Research StudiesRespiratory Support and Mechanisms

Cited by 678

Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

Luke, J. J., Lemons, J. M., Karrison, T. G., Pitroda, S. P., Melotek, J. M., Zha, Y., Al-Hallaq, H. A., Arina, A., Khodarev, N. N., Janisch, L., et al. (2018) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersAdvanced Radiotherapy Techniques

Cited by 588

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

Kurzrock, R., Sherman, S. I., Ball, D. W., Forastiere, A. A., Cohen, R. B., Mehra, R., Pfister, D. G., Cohen, E. E. W., Janisch, L., Nauling, F., et al. (2011) · Journal of Clinical Oncology

Thyroid Cancer Diagnosis and TreatmentRenal cell carcinoma treatment

Cited by 550

A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbital

INNOCENTI, F., UNDEVIA, S., RAMIREZ, J., MANI, S., SCHILSKY, R., VOGELZANG, N., PRADO, M., & RATAIN, M. (2004) · Clinical Pharmacology & Therapeutics

Cancer therapeutics and mechanismsPharmacogenetics and Drug Metabolism

Cited by 57

Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs

Gao, W., Liu, J., Musante, C. J., Zhu, H., Thompson, M., Shah, M., Cao, Y., Ivaturi, V., Conaway, M. R., Bottino, D., et al. (2025) · Clinical Pharmacology & Therapeutics

Statistical Methods in Clinical TrialsPharmaceutical studies and practices

Cited by 2